

Specialty Quantity Limit Program

Mimrylo

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Mimrylo	rusfertide

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Mimrylo 9.5 mg single-dose vials	4 per 28 days
Mimrylo 19 mg single-dose vials	4 per 28 days
Mimrylo 28 mg single-dose vials	4 per 28 days
Mimrylo 41 mg single-dose vials	8 per 28 days
Mimrylo 54 mg single-dose vials	8 per 28 days

FDA-recommended Dosing

The recommended starting dose is 19 mg subcutaneously once weekly.

Reference number(s)
7601-H

The recommended weekly dosage range is 9.5 mg to 108 mg. Dose modifications can be made after a minimum of 2 weeks and are based on medical judgement to reduce or to maintain hematocrit at the recommended level below 45% and prevent anemia and other drug-related toxicities.

References

1. Mimrylo [package insert]. Cambridge, MA: Takeda Pharmaceuticals America, Inc.; August 2026.